Friday, May 3, 2019

Is Schizophrenia proteomics is the biomarker path to laboratory medicine?

Schizophrenia is a mental disorder that usually occurs in late adolescence or in early adulthood usually characterized by delusions, hallucinations, and other cognitive difficulties, schizophrenia can often be a lifelong struggle.

As a complex combination of the genetic, neurodevelopmental, and environmental components, schizophrenia is one of the most difficult human disorders to be studied at the molecular level. There is a countless combination of biochemical and environmental links that leads to intricate webs of molecular interactions, which are not specific to the brain, hampering the identification of not only the causes and consequences of schizophrenia but also the discovery of biomarkers
The Proteomic profiling studies have indicated that the oligodendrocyte dysfunction plays a key role in schizophrenia which consists of transcriptomic findings.

Biomarkers are a biologic feature that can be used to measure the presence or progress of a disease or the effects of treatment.
Biomarkers may be in any form of genes, proteins and other molecules, or morphological characteristics. Depending on the information that is provided, biomarkers may be used in diagnostics as the prediction tools in the field of subclinical markers, risk or vulnerability markers, or as diseases signatures like the disease markers, stage or progression markers.

Even though the pathophysiology of schizophrenia remains unclear, there is an increasing body of evidence that several molecular pathways are involved. Most findings point to the direction of malfunctioning of the glutamate pathway.

Proteomics as a biomarker for the exploration of mental disorders:

The proteome is the entire set of proteins produced or modified by an organism and varies with time, biological requirements, stress, and other environmental factors. Proteomics refers to a large-scale and global analysis of the proteins in a system, at a specific point in time under a determined condition. Proteomics aims to obtain a more global and integrated view of biology by studying all the proteins of a cell rather than each one individually. Hence the protein profiling may better reflect dynamic pathophysiological processes.

Meta-analyses of several linkage studies, correlations with some chromosomal regions, however, they do not approach the acceptable genome-wide significance. While there has been a successful mapping of genes for monogenic or Mendelian disorders, linkage studies are inadequate for complex multi-factorial disorders like schizophrenia.

The development of high-throughput technologies of proteomic analysis has introduced a new era of biomarker discovery. For complex, multifactorial disorders, ‘molecular fingerprinting’ via the identification and characterization of biomarker profiles has enabled greater diagnostic resolution between closely related disease phenotypes. For psychiatric disorders, profiling allows for the generation of predictive models regardless of the disease causes, which generally remain largely unknown. Furthermore, it holds promise not only for predicting the onset of a disorder but also its course and outcome.

Monday, April 29, 2019

LabMedPath 2019

About Conference

16th Annual Conference on Laboratory Medicine &Pathology  will be held during December 09-10, 2019 at Dubai, UAE. The theme of the conference is LabMedPath: ELEMENTS OF LABORATORY AS CORE IN DIAGNOSING DISEASES” and to encourage young minds and their research abilities by providing an opportunity to meet the experts at LabMedPath 2019.
LabMedPath 2019 anticipates hundreds of delegates including international keynote lectures and oral presentations by renowned speakers and poster presentations by students, Exhibitions, and delegates all around the world which will craft a platform for global promotion and effective development in this field. It provides international networking and opportunities for collaborations with worldwide companies and industries.
This global event will be an excellent opportunity for pathologists and other professionals. We are anticipating around 60+ speakers and over 400 delegates for this esteemed LabMedPath 2019.
Laboratory medicine:
Laboratory medicine is that the branch of medications amid which examples of tissue, liquid or diverse matter inspected outside of the individual, for the most part inside the lab.
The pathology is the investigation of infection by and large, fusing an extensive variety of natural science inquiry about divisions and therapeutic fields which incorporates plant pathology and veterinary pathology or all the more particularly it is to depict work inside the contemporary medicinal field of "general pathology," which incorporates the analyze of a specific sickness—by and large through examination of tissue, cell, and body liquid examples. The medico honing pathology is known as a pathologist. The real divisions of pathology are anatomical pathology and clinical pathology.
Pathology is a noteworthy field in current therapeutic practice and analysis. The worldwide advanced pathology showcase, esteemed at $1.98 billion out of 2012, is evaluated to reach $5.7 billion by 2020. The In vitro diagnostics showcase income is relied upon to reach $74.65 billion by 2020, from the market estimation of $53.32 billion of every 2013, at a CAGR of 5.34% amid 2014-2020. Analytic Medicine has $35 billion markets, development 5-7% yearly. Pathology labs will take around $15-16 billion in income, and they will spend about 12% of their incomes with their providers all finished USA.
Pathology is an underlying driver to comprehend the instrument of an ailment. It is a subject for the experts who look past the clinical desires. Pathology 2016 assembles every one of the social butterflies under one top of current advances.

Conference Highlights

Special Issues

  •  All accepted abstracts will be published in respective Supporting International Journals.
  •  Abstracts will be provided with Digital Object Identifier by Cross Ref.

See more at :-